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Uveal melanoma arises in the eye, and it spreads to distant organs in almost half of
patients, leading to a fatal outcome. To metastasize, uveal melanoma cells must
transmigrate into and out of the microvasculature, crossing the monolayer of
endothelial cells that separates the vessel lumen from surrounding tissues. We
investigated how human uveal melanoma cells cross the endothelial cell
monolayer, using a cultured cell system with primary human endothelial cell
monolayers on hydrogel substrates. We found that uveal melanoma cells
transmigrate by a novel and unexpected mechanism. Uveal melanoma cells
intercalate into the endothelial cell monolayer and flatten out, assuming a shape
and geometry similar to those of endothelial cells in the monolayer. After an
extended period of time in the intercalated state, the uveal melanoma cells round
up and migrate underneath the monolayer. VCAM is present on endothelial cells,
and anti-VCAM antibodies slowed the process of intercalation. Depletion of BAP1,
a known suppressor of metastasis in patients, increased the amount of
transmigration of uveal melanoma cells in transwell assays; but BAP1 depletion did
not affect the rate of intercalation, based on movies of living cells. Our results reveal
a novel route of transendothelial migration for uveal melanoma cells, and they
provide insight into the mechanism by which loss of BAP1 promotes metastasis.

Introduction
Melanomas are highly aggressive cancers that often metastasize and result in
patient death [1]. For melanomas that arise in the pigmented uveal layers of the
eye, almost half of patients develop fatal metastatic disease, even after the tumorbearing eye is surgically removed [2]. Uveal melanomas (UMs) present as discrete
masses between the thick, fibrous sclera and the retina, often pushing the retina

PLOS ONE | DOI:10.1371/journal.pone.0115472 December 15, 2014

1 / 16

Transendothelial Migration by Melanoma Cells

into the vitreous space [3]. The highly vascular nature of the uvea provides a ready
outlet for the spread of UM cells to distant organs through the bloodstream [4].
The anatomy of the eye, including its notable lack of lymphatic vessels, implies
that local spread of UM to surrounding tissues is rare [5]. Therefore, the spread of
UM cancer cells by the hematogenous route is critical to the morbidity and
mortality of the disease, and it would be important to understanding the
mechanism by which UM cells cross the endothelial barrier as they enter and exit
the bloodstream.
Despite advances in treatment for the primary tumor in the eye, the mortality
rate for UM has not changed, due to our inability to prevent or treat metastases
[6]. UM cells have been detected in the circulation of patients at the time of
diagnosis and after removal of the primary tumor. Patients with clinically
detectable metastatic disease also have circulating UM cells [7], and the number of
circulating cells correlates with the size and number of metastatic lesions [8].
Surprisingly, circulating UM cells have also been found at the time of diagnosis of
the primary tumor in patients who did not proceed to develop metastases [7, 9].
Therefore, the ability of UM cells to enter the bloodstream appears not to predict
the ability of the cells to metastasize, suggesting that the metastatic potential of a
given tumor depends on the ability of the cells to exit the bloodstream via the
microvasculature, in order to invade and colonize distant organs.
The vessels of the microvasculature are important conduits for exchange of
metabolites, and they provide immune cells with access to tissues. The endothelial
cells (ECs) that line these vessels inform circulating immune cells of the state of
the surrounding tissue, and they recruit and activate immune cells to migrate into
the surrounding tissue under a variety of physiological and pathological
conditions [10]. ECs maintain the integrity of the vasculature during
transendothelial migration (TEM) by immune cells by creating, maintaining and
closing passages for immune cells to cross the EC monolayer [11–13].
Cancer cells appear to co-opt the process of TEM when they transit the vessel
wall, entering and leaving the circulation [14–16]. These transmigration events
can occur in the absence of inflammatory signals, suggesting that other factors,
such as mechanical stress or properties of the surrounding tissue, may help to
regulate the timing and efficiency [17]. We have developed a cell-culture model of
TEM using monolayers of primary human dermal microvascular ECs
(HDMVECs) on hydrogels with stiffnesses similar to normal human tissue [18].
Here, we used this model to study the transmigration of UM cells across EC
monolayers. We report the discovery that UM cells transmigrate via a novel
process that includes intercalation into the EC monolayer, after which they
migrate under the monolayer to invade interstitial tissue. We find that this process
requires VCAM-mediated adhesion between UM cells and ECs and that loss of the
metastasis suppressor BAP1 enhances TEM.
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Materials and Methods
Chemicals and reagents were obtained from Fisher Scientific (Pittsburgh, PA) or
Sigma-Aldrich (Saint Louis, MO), unless stated otherwise.

Cell Culture
Cells were cultured at 37 ˚C in 5% CO2. Primary HDMVECs were obtained from
Lonza (Allendale, NJ) and cultured in EBM-2 base medium supplemented with
the EGM-2 MV kit. HDMVECs were not used after 9 passages. Human 92.1 and
OCM-1A UM cells were derived by and the generous gifts of Drs. Martine Jager
(Laboratory of Ophthalmology, Leiden University) [19] and June Kan-Mitchell
(Biological Sciences, University of Texas at El Paso) [20], respectively. Both cell
lines were grown in RPMI 1640 medium (Life Technologies, Carlsbad, CA)
supplemented with 10% FBS and antibiotics.

Lentiviral Constructs and Plasmids
Lentiviral-based constructs were used for expression and knockdown experiments.
Lentiviral pBOB-GFP was used to express GFP in HDMVEC cells. Lentiviral
pLKO.1 shRNA expression plasmids targeting GFP (clonetechGfp-438s1c1) and
BAP1 (NM_004656.2-2658s1c1) were obtained from The RNAi Consortium
(TRC) via the Children’s Discovery Institute/Genome Sequencing Center at
Washington University. Viral production and infections were carried out
according to consortium recommendations (Broad Institute). The F-tractin
expression construct (ptdTomato-N1-F-tractin) [21] was a generous gift of Dr.
Michael Schell (Department of Neurology, Uniformed Services University of the
Health Sciences).

Immunostaining and antibodies
Fixation was carried out by adding an equal volume of 26 fixative (PBS with 4%
paraformaldehyde and 0.4% glutaraldehyde) to EC monolayers in EGM-2 MV
medium 15 min, 1 hr, 3 hrs, and 6 hrs after addition of UM cells. After 15 min at
37 ˚C, cells were permeabilized with 0.1% Triton X-100 in PBS for 5 min, washed
with PBS, and blocked with 2% fish gelatin (Sigma-Aldrich) in PBS. Primary and
secondary antibodies were diluted in 2% fish gelatin in PBS. Primary antibodies
included mouse monoclonal anti-cortactin (Millipore, Billerica, MA), mouse
monoclonal anti-E-cadherin (BD Biosciences, Franklin Lakes, NJ), mouse
monoclonal anti-N-cadherin (BD Biosciences), mouse monoclonal anti-VCAM
(R&D Systems, Minneapolis, MN), rabbit polyclonal anti-S100 (DakoCytomation,
Denmark), and rabbit polyclonal anti-VE-cadherin (Cell Signaling, Danvers, MA).
F-actin was visualized using Alexa-fluor-conjugated phalloidin (Life Technologies).
Secondary antibodies were Alexa-fluor conjugates (Life Technologies), and the
mounting agent was ProLong Gold (Life Technologies). Cells were imaged with an
inverted microscope (Olympus IX72) using a 406 objective.
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Live Cell Imaging and Analysis
Hydrogels on coverslips were prepared with polyacrylamide as described [18]. The
hydrogels were coated with fibronectin (10 mg/mL in PBS) by overnight
incubation at 4 ˚C and washed with PBS. HDMVECs were plated on the
fibronectin-coated hydrogel substrates and incubated overnight to allow
formation of monolayers. Monolayers were inspected by phase-contrast microscopy to ensure that ECs covered the substrate completely, without defects, before
transmigration assays were performed. For blocking experiments, mouse
monoclonal antibodies against ICAM1 (BBIG-I1, R&D Systems) or VCAM
(BBIG-V1, R&D Systems) were diluted into EGM-2 MV media and added to
monolayers 1 hr before assaying TEM.
Melanoma cells were added to HDMVEC monolayers in EGM-2 MV culture
medium and placed into an environmental chamber (Stage Top Incubator, Tokai
Hit, Shizuoka-ken, Japan) with 5% CO2 at 37 ˚C on either an inverted wide-field
microscope (Olympus IX72) or an inverted laser-scanning confocal microscope
(Olympus FV1200). Wide-field fluorescence and DIC images were captured at 12s intervals with a 106 or a 406 objective. Confocal fluorescence and DIC images
were captured at 20-s intervals with a 606 objective.

Transwell assays
Transwell chambers (Corning) with 5-mm pore-size inserts were coated with
10 mg/mL fibronectin in PBS overnight at 4 ˚C. HDMVECs were plated on the
chamber membrane by adding 0.66105 cells in 100 mL HDMVEC media. After
24 hrs, the media was replaced with fresh HDMVEC media (100 mL in the top
chamber and 600 mL in the bottom chamber). For blocking experiments,
antibodies against ICAM1 or VCAM as noted above were diluted into EGM-2 MV
media and added to monolayers 1 hr before TEM. UM cells (105 in 100 mL
serum-free RPMI medium) were added to the EC monolayer. The medium in the
bottom chamber was replaced with RPMI medium containing 10% FBS to act as a
chemoattractant. The chambers were incubated at 37 ˚C for 7 hrs to allow for
transmigration. UM cells were collected from the bottom chamber every hr.

Results
UM cells Intercalate into EC Monolayers
We asked how UM cells interact with monolayers of primary human ECs grown
on soft substrates. Immune cells move rapidly and efficiently through EC
monolayers, based on movies of living cells in several studies [12], which we
confirmed in our system [22]. The behavior of migrating melanoma cells was
strikingly different. UM cells, both the 92.1 and OCM-1A cell lines, inserted
themselves between ECs in HDMVEC monolayers and assumed a flattened
morphology, appearing to join the monolayer in the manner of an EC. (Fig. 1A,
S1 Movie). This intercalation occurred exclusively at EC cell-cell junctions. No
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Fig. 1. UM cells transmigrate through a novel intercalation process. A) Frames from DIC movies of UM
cells, 92.1 and OCM-1A, intercalating into the endothelial monolayer (S1 Movie). Arrows indicate intercalation
events. Scale bar 550 mm. B) Plot of the percentage of cells that achieve intercalation over time, based on the
movies.
doi:10.1371/journal.pone.0115472.g001

cells followed a transcellular route through a single EC, in striking contrast to the
behavior of migrating immune cells [23].
The timing of the initiation of intercalation differed somewhat for the two UM
cells lines (Fig. 1B). OCM-1A cells were faster, with 67% initiating TEM by 1 hr
after addition, compared with 29% of 92.1 cells (Fig. 1B). Within this time frame,
essentially all UM cells that intercalated into the monolayer remained in the
intercalated state, without migrating through and under the monolayer or
reversing course to move up and back out.

Stepwise Progression of Intercalation
We examined the steps by which UM cells intercalated into EC monolayers, using
dual-color live-cell imaging. We followed actin dynamics in UM cells by
expressing the fluorescent marker tdTomato-F-tractin; the ECs expressed GFP.
S2 Movie is a representative example, and selected frames are shown in Fig. 2. UM
cells settled onto the HDMVEC monolayers and remained relatively stationary,
displaying little migration across the surface of the monolayer, in contrast to the
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Fig. 2. Invasive projections are rich in F-actin. Frames from S2 Movie show a UM cell (OCM-1A) with Ftractin-labeled actin filaments intercalating between ECs in a monolayer. Arrows indicate F-actin-rich
protrusions that transiently probe the space under the monolayer. The UM cell completes intercalation and
maintains contact with adjacent ECs. Scale bar 520 mm.
doi:10.1371/journal.pone.0115472.g002

active migration displayed by immune cells [12, 22–24]. During this time, UM
cells extended protrusions that appeared to probe the surface of the EC monolayer
(Fig. 2, second row). When a UM cell protrusion contacted an EC cell-cell
junction, the protrusion sometimes became attached, after which the UM cell
moved to center itself over the point of contact.
Next, a small opening appeared in the EC cell junction, and the UM cell
extended protrusions through the opening, which contacted the substrate (S2
Movie). The UM cell maintained contact with the substrate, and the opening
between the ECs expanded (Fig. 2, third row). Eventually, the opening expanded
to the size and dimensions of the UM cell, and the UM cell expanded and
flattened, assuming a morphology similar to that of a typical EC in the monolayer.
The UM cell maintained close contact with its EC monolayer neighbors (Fig. 2,
fourth row). The UM cell remained intercalated within the monolayer for an
extended period of time (Fig. 2, last row).

UM Cell Migration after Intercalation
We extended the time frame of our experiments to observe whether and how UM
cells would exit the EC monolayer. During the process of intercalation, UM cells
extended numerous transient projections underneath the EC monolayer (Fig. 3A,
S3 Movie). As time progressed, cells in the intercalated state continued to extend
these processes, released their contacts with their EC neighbors and migrated
underneath the EC monolayer.
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Fig. 3. Melanoma transmigration is a stepwise process. A) Frames from S3 Movie showing transmigration
of a UM cell (OCM-1A) expressing F-tractin (pseudocolored to show fluorescence intensity). Time in min is
indicated in the upper left of each panel. Below each panel is an x-z slice through the intercalating cell, taken
at the position indicated in the x-y image. B and C) Timing of steps of UM cell transmigration, based on results
from three 12-hr movies. Panel B shows the percentage of cells in each state at a given time, and panel C
plots the results as a cumulative percentage of cells that have undergone a step. Scale bar 525 mm.
doi:10.1371/journal.pone.0115472.g003
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To examine the dynamics of intercalation and migration, we collected longer
(12-hr) movies of UM cells on EC monolayers. We used OCM-1A cells because
their rate of intercalation was higher than that of 92.1 cells. The OCM-1A cells
interacted with the EC monolayers immediately on addition, as described above,
with approximately half of cells initiating intercalation by 65 min (Fig. 3B). The
first cells completed intercalation at 20 min after initiation, approximately half of
cells intercalated by 130 min, and 90% by 12 hrs (Fig. 3B).
UM cells remained intercalated for a period of time and then migrated
underneath the EC monolayer. Some UM cells remained intercalated for the
duration of the movie (.11 hrs). Cells continued to extend transient protrusions
under the monolayer during intercalation, but the first occurrences of persisting
projections were at ,90 min. By 12 hr, at the end of the movie, ,45% of cells
displayed persisting projections under the monolayer (Fig. 3B). UM cells began to
migrate under the monolayer and away from their intercalated positions at
,135 min, and 37% of UM cells had migrated away from their positions by 12 hr
(Fig. 3B).
No UM cells moved back up and out of the monolayer, presumably because
their adhesion to the fibronectin in the hydrogel substrate favored their
movement under the monolayer.

UM Transmigration is Regulated by Cell Adhesion Molecules
We asked whether UM cells initiated and maintained contact with ECs through
known cell adhesion receptors. When immune cells perform TEM, they bind to
ICAM1 on the surface of activated ECs [13]. For UM cell TEM, ECs are not
expected to be activated in the metastatic tissue target; therefore, the EC monolayers
were not treated with inflammatory activators in our system. However, ICAM1 and
VCAM are expressed constitutively on ECs, albeit at lower levels than on activated
ECs. In addition, ECs use VE-cadherin to adhere to each other at cell junctions. UM
cells express E-cadherin and N-cadherin [25], and VE-cadherin has been observed
on cutaneous melanoma cells [26].
We observed accumulation of VCAM on ECs at the point of their initial contact
with transmigrating UM cells, by immunofluorescence (Fig. 4). This accumulation was transient, and VCAM was not observed at junctions between UM cells
and ECs after intercalation was complete (Fig.ure 4). Neither VE-cadherin, Ecadherin, nor N-cadherin was observed at UM - EC junctions (Fig.ure 4 and data
not shown).
We tested for functional roles by adding blocking antibodies to ICAM1 and
VCAM. Anti-ICAM1 decreased the rate of intercalation by ,50%, based on 1-hr
movies (Fig.ure 5A), but the Abs had no effect on the level of TEM in 5-hr
transwell assays (Fig.ure 5B). Anti-VCAM had a similar inhibitory effect in 1-hr
movies; however, the level of TEM in transwell assays increased by a factor of four
(Fig.ure 5). Together, these results indicate that integrin-mediated interactions are
important and that intercalation into and migration out of the EC monolayer
depend on different adhesive molecules.

PLOS ONE | DOI:10.1371/journal.pone.0115472 December 15, 2014

8 / 16

Transendothelial Migration by Melanoma Cells

Fig. 4. Localization of VCAM and VE-cadherin in UM cells interacting with ECs. Cell preparations were
fixed and stained at indicated times after addition of UM cells. Anti-VE-cadherin stains junctions between ECs
in the monolayer but not junctions between UMs and ECs. Anti-VCAM fluorescence appears transiently on
ECs at the point of contact with UM cells, indicated by yellow stars, at the start of transmigration. Scale bar
525 mm.
doi:10.1371/journal.pone.0115472.g004

Loss of BAP1 enhances UM transmigration
BAP1 loss-of-function mutations promote the metastatic spread of UM cancers in
patients [27], and TEM should be a rate-limiting step of metastasis. Therefore, we
asked whether loss of BAP1 affected transmigration of UM cells in our model of
TEM. We depleted BAP1 in UM cells by lentiviral infection of cell with shRNA
targeting BAP1.
First, we used conventional transwell assays, with ECs forming monolayers on
the surface of the transwell filter. Depletion of BAP1 doubled the number of
transmigration events by UM cells in these assays (Fig.ure 6A). Next, we used
movie analysis of living cells to examine BAP1-depleted UM cells interacting with
EC monolayers. The rate and efficiency of intercalation were similar to those of
control UM cells over one hr (Fig.ure 6B). We conclude that the effect of loss of
BAP1, seen in the transwell assay, is on later steps in transmigration, after those
observed in the movie analysis of intercalation.
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Fig. 5. Blocking Abs against VCAM and ICAM1 affect the timing of TEM. A) Intercalation of UM cells
undergoing TEM based on movies, as in Fig. 1. Blocking antibodies to ICAM1 and VCAM decreased the rate
of intercalation. B) Effect of blocking Abs on bulk transmigration of UM cells assayed in transwell chambers.
doi:10.1371/journal.pone.0115472.g005

Discussion
We investigated the cellular and molecular mechanisms used by UM cells to
transmigrate through EC monolayers. We made three important discoveries. First,
UM cells move through the EC monolayer in a remarkable process not previously
observed in studies of transendothelial migration. The UM cells intercalate into
the EC monolayer, where they assume a flattened and spread morphology similar
to an EC in the monolayer. They remain intercalated for an extended period time,
before migrating through and underneath the monolayer. Second, we discovered a
functional role for integrin-based adhesion in the intercalation process. Third,
BAP1, a critical suppressor of metastasis by UM cells, has a role in the overall
efficiency of transmigration, but not on the intercalation process.

UM Cells Transmigrate Through a Series of Distinct Steps
We found that UM cells perform TEM by a specific multi-step route
(diagrammed in Fig.ure 7A), which differs substantially from that taken by
immune cells. First, UM cells probe the apical surface of the EC monolayer, and
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Fig. 6. Effects of depletion of BAP1 on transendothelial migration. A) TEM of UM cells based on transwell
assays after lentiviral induction of shRNA targeting BAP1 or GFP. B) Intercalation of UM cells into EC
monolayers, based on movies.
doi:10.1371/journal.pone.0115472.g006

they extend processes that attach to cell junctions between adjacent ECs. Next,
UM cells enter and enlarge the space between ECs. The UM cells proceed to
flatten, while maintaining contact with the ECs, essentially intercalating
themselves into the monolayer with the position and shape of an EC. The UM
cells stay intercalated in the EC monolayer for a period of time. They extend
processes underneath the EC monolayer, contacting the fibronectin-coated
hydrogel substrate. Finally, the UM cells release their attachments to the ECs, and
then move under the EC monolayer and migrate between the monolayer and the
substrate.
One notable feature of this process is the amount of time that the UM cells
spend in the intercalated state, relative to the time used for entering and exiting
the intercalated state (Fig.ure 7B). Both uveal and cutaneous melanoma cells have
been observed to undergo ‘‘vasculogenic mimicry,’’ taking on an endothelial
morphology and forming tubular networks in 3D-culture systems [28, 29]. In
addition, cutaneous human melanoma cells can contribute to vascular channels in
mouse xenograft tissues [30]. Cutaneous melanoma cells express VE-cadherin in
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Fig. 7. Timing of TEM steps for UM cells. A) Diagram depicting the steps of TEM used by UM cells. B) Plot of time spent in each phase of intercalation.
The data include only cells that eventually disengaged from intercalation; many cells were still intercalated at 12 hrs and could not be assessed for duration
of intercalation. Red bars indicate medians.
doi:10.1371/journal.pone.0115472.g007

the process of vasculogenic mimicry [26], but we did not observe VE-cadherin on
UM cells intercalated into EC monolayers (Fig.ure 4). Thus, the intercalated state
observed in our system appears to be a novel interaction between UMs and ECs
distinct from vasculogenic mimicry. We speculate that the intercalation process
may be a critical component of metastasis in tissues and the organism.

Functional Roles for Integrin-based Adhesion in UM Intercalation
When immune cells cross the endothelium, immune-cell integrins bind to ICAM1
on the surface of the EC [13]. While UM cells do not express the beta2 integrins
characteristic of immune cells [31], they do express several beta1 integrins [32],
including alpha4beta1, which binds VCAM and is upregulated on invasive UM
cells [33]. Neither UM cells nor ECs express ligands for ICAM1, so we were
surprised to find an effect on intercalation with anti-ICAM1 antibodies. Antibody
crosslinking of ICAM1 can activate the ICAM1 pathway in ECs [34], and this may
be affecting EC activity in our movies. We observed accumulation of VCAM on
ECs at the initiation of TEM, which was lost when intercalation was compete.
Using blocking antibodies against VCAM and ICAM1, we observed a decreased
rate of intercalation of UM cells into the EC monolayer, based on movie assays.
However, anti-VCAM increased the overall level of transmigration in transwell
assays, while anti-ICAM1 had no effect in this assay. VCAM and ICAM1 both
contribute to the process of TEM, but to different extents and probably in
different roles.

BAP1 Depletion Enhances TEM
Human uveal melanoma tumors with loss-of-function mutations in BAP1 are
more likely to metastasize [27]. Circulating tumor cells must presumably execute
TEM as part of entering tissues during the process of metastasis. Therefore, we

PLOS ONE | DOI:10.1371/journal.pone.0115472 December 15, 2014

12 / 16

Transendothelial Migration by Melanoma Cells

hypothesized that decreasing BAP1 might increase the ability of UM cells to
perform TEM in our model system. As predicted, shRNA-mediated depletion of
BAP1 increased the overall rate of TEM by UM cells in transwell assays. However,
movies of UM cells undergoing transmigration revealed no effect of BAP1
depletion on the rate of UM cell intercalation into the monolayer. Thus, BAP1
depletion appears to affect later steps in transmigration of UM cells, such as
disengagement from and invasion underneath the monolayer.
The differences in rates of intercalation between the two UM cell lines were
notable (Fig.ure 2B). Both the 92.1 and OCM-1A lines were derived from spindle
type B tumors [19, 20], and both lines maintain this spindle morphology in
culture, suggesting that the intercalation rate differences do not result from
alterations in cell morphology. Depletion of BAP1 from these cell lines makes
them less spindle-like in culture [35]. We show here that BAP1-depleted cells are
also more invasive, suggesting a possible link between the later steps in
transmigration with cell morphology.
In cutaneous melanoma, pigmentation has been associated with tumor cell
function [36], poor prognosis [37], and resistance to therapies [38, 39]. In uveal
melanoma, tumor pigmentation has been associated with tumor size [5], which is
associated with poor prognosis [1]. The 92.1 and OCM-1A cell lines both produce
melanin [19, 20], and depletion of BAP1 decreases the expression of genes
involved in melanogenesis [35]. Thus, the cell survival advantage associated with
increased melanin and the metastatic advantage of increased transendothelial
migration appear to be independent.

Concluding Remarks
We discovered that UM cells transmigrate through EC monolayers by a novel
mechanism in which they intercalate into the EC monolayer and assume an EClike morphology. Intercalation occurs quickly, within the first hour for the
majority of cells. The rate-limiting step in the transmigration process appears to
be disengagement of the UM cells from the EC monolayer and migration onto the
underlying substrate. Integrin-based adhesion, especially involving VCAM,
appears to play a role in maintaining adhesion of UM cells to ECs. BAP1 depletion
appears to promote UM cell migration underneath the monolayer. This system
may be an important new model for the study of metastasis in uveal melanoma.

Supporting Information
S1 Movie. UM cells transmigrate through a novel intercalation process. DIC
movies of UM cells, 92.1 and OCM-1A, intercalating into the endothelial
monolayer. Scale bar 550 mm. Frames were collected at a rate of one per 12 sec.
The movies play at a rate of 30 frames per sec.
doi:10.1371/journal.pone.0115472.s001 (AVI)
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S2 Movie. Invasive projections are rich in F-actin. UM cell (OCM-1A) with Ftractin-labeled actin filaments intercalating between ECs in a monolayer. F-actinrich protrusions are seen transiently probe the space under the monolayer. The
UM cell completes intercalation and maintains contact with adjacent ECs. Scale
bar 520 mm. Frames were collected at a rate of one per 12 sec. The movies play at
a rate of 15 frames per sec.
doi:10.1371/journal.pone.0115472.s002 (AVI)
S3 Movie. Melanoma transmigration is a stepwise process. Laser-scanning
confocal movie of transmigration of a UM cell (OCM-1A) expressing F-tractin
(pseudo-colored to show fluorescence intensity). Scale bar 525 mm. Frames were
collected at a rate of one per 20 sec. The movies play at a rate of 30 frames per sec.
doi:10.1371/journal.pone.0115472.s003 (AVI)

Author Contributions
Conceived and designed the experiments: MDO JAC. Performed the experiments:
MDO JL. Analyzed the data: MDO JAC. Contributed reagents/materials/analysis
tools: MDO JL JAC. Wrote the paper: MDO JL JAC.

References
1. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, et al. (2009) Final version of 2009
AJCC melanoma staging and classification. J Clin Oncol 27: 6199–6206.
2. Singh AD, Bergman L, Seregard S (2005) Uveal melanoma: epidemiologic aspects. Ophthalmol Clin
North Am 18: 75–84, viii.
3. COMS (2001) Assessment of metastatic disease status at death in 435 patients with large choroidal
melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. Arch Ophthalmol
119: 670–676.
4. Clarijs R, Schalkwijk L, Ruiter DJ, de Waal RM (2001) Lack of lymphangiogenesis despite
coexpression of VEGF-C and its receptor Flt-4 in uveal melanoma. Invest Ophthalmol Vis Sci 42: 1422–
1428.
5. COMS (1998) Histopathologic characteristics of uveal melanomas in eyes enucleated from the
Collaborative Ocular Melanoma Study. COMS report no. 6. Am J Ophthalmol 125: 745–766.
6. Yonekawa Y, Kim IK (2012) Epidemiology and management of uveal melanoma. Hematol Oncol Clin
North Am 26: 1169–1184.
7. Callejo SA, Antecka E, Blanco PL, Edelstein C, Burnier MN (2006) Identification of circulating
malignant cells and its correlation with prognostic factors and treatment in uveal melanoma. A
prospective longitudinal study. Eye 21: 752–759.
8. Mazzini C, Pinzani P, Salvianti F, Scatena C, Paglierani M, et al. (2014) Circulating tumor cells
detection and counting in uveal melanomas by a filtration-based method. Cancers (Basel) 6: 323–332.
9. Keilholz U, Goldin-Lang P, Bechrakis NE, Max N, Letsch A, et al. (2004) Quantitative detection of
circulating tumor cells in cutaneous and ocular melanoma and quality assessment by real-time reverse
transcriptase-polymerase chain reaction. Clin Cancer Res 10: 1605–1612.
10. Vestweber D (2007) Adhesion and signaling molecules controlling the transmigration of leukocytes
through endothelium. Immunol Rev 218: 178–196.
11. Muller WA (2009) Mechanisms of transendothelial migration of leukocytes. Circ Res 105: 223–230.
12. Sage PT, Carman CV (2009) Settings and mechanisms for trans-cellular diapedesis. Front Biosci
(Landmark Ed) 14: 5066–5083.

PLOS ONE | DOI:10.1371/journal.pone.0115472 December 15, 2014

14 / 16

Transendothelial Migration by Melanoma Cells

13. Wittchen ES (2009) Endothelial signaling in paracellular and transcellular leukocyte transmigration.
Front Biosci (Landmark Ed) 14: 2522–2545.
14. Zervantonakis IK, Hughes-Alford SK, Charest JL, Condeelis JS, Gertler FB, et al. (2012) Threedimensional microfluidic model for tumor cell intravasation and endothelial barrier function. Proc Natl
Acad Sci U S A 109: 13515–13520.
15. Reymond N, d’Agua BB, Ridley AJ (2013) Crossing the endothelial barrier during metastasis. Nat Rev
Cancer 13: 858–870.
16. Fazakas C, Wilhelm I, Nagyoszi P, Farkas AE, Hasko J, et al. (2011) Transmigration of melanoma
cells through the blood-brain barrier: role of endothelial tight junctions and melanoma-released serine
proteases. PLoS One 6: e20758.
17. Stroka KM, Aranda-Espinoza H (2011) Effects of Morphology vs. Cell-Cell Interactions on Endothelial
Cell Stiffness. Cell Mol Bioeng 4: 9–27.
18. Onken MD, Mooren OL, Mukherjee S, Shehan S, Li J, et al. (2014) Endothelial monolayers and
transendothelial migration depend on mechanical properties of substrate. Cytoskeleton in revision.
19. De Waard-Siebinga I, Blom DJ, Griffioen M, Schrier PI, Hoogendoorn E, et al. (1995) Establishment
and characterization of an uveal-melanoma cell line. Int J Cancer 62: 155–161.
20. Kan-Mitchell J, Mitchell MS, Rao N, Liggett PE (1989) Characterization of uveal melanoma cell lines
that grow as xenografts in rabbit eyes. Invest Ophthalmol Vis Sci 30: 829–834.
21. Johnson HW, Schell MJ (2009) Neuronal IP3 3-kinase is an F-actin-bundling protein: role in dendritic
targeting and regulation of spine morphology. Mol Biol Cell 20: 5166–5180.
22. Mooren OL, Li J, Nawas J, Cooper JA (2014) Endothelial Cells Use Dynamic Actin to Facilitate
Lymphocyte Transendothelial Migration and Maintain the Monolayer Barrier. Mol Biol Cell.
23. Muller WA (2011) Mechanisms of leukocyte transendothelial migration. Annu Rev Pathol 6: 323–344.
24. Mukherjee S, Kim J, Mooren OL, Cooper JA (2014) Role of Cortactin Homolog HS1 in
Transendothelial Migration of Natural Killer Cells. PLoS One in revision.
25. Anastassiou G, Tschentscher F, Zeschnigk M, Bornfeld N (2002) Cadherin expression in uveal
melanoma. Exp Eye Res 74: 423–425.
26. Hendrix MJ, Seftor EA, Meltzer PS, Gardner LM, Hess AR, et al. (2001) Expression and functional
significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry. Proc
Natl Acad Sci U S A 98: 8018–8023.
27. Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, et al. (2010) Frequent mutation of BAP1 in
metastasizing uveal melanomas. Science 330: 1410–1413.
28. Folberg R, Arbieva Z, Moses J, Hayee A, Sandal T, et al. (2006) Tumor cell plasticity in uveal
melanoma: microenvironment directed dampening of the invasive and metastatic genotype and
phenotype accompanies the generation of vasculogenic mimicry patterns. Am J Pathol 169: 1376–1389.
29. Hendrix MJ, Seftor EA, Hess AR, Seftor RE (2003) Vasculogenic mimicry and tumour-cell plasticity:
lessons from melanoma. Nat Rev Cancer 3: 411–421.
30. Mihic-Probst D, Ikenberg K, Tinguely M, Schraml P, Behnke S, et al. (2012) Tumor cell plasticity and
angiogenesis in human melanomas. PLoS One 7: e33571.
31. Onken MD, Worley LA, Ehlers JP, Harbour JW (2004) Gene expression profiling in uveal melanoma
reveals two molecular classes and predicts metastatic death. Cancer Res 64: 7205–7209.
32. Baker JK, Elshaw SR, Mathewman GE, Nichols CE, Murray AK, et al. (2001) Expression of integrins,
degradative enzymes and their inhibitors in uveal melanoma: differences between in vitro and in vivo
expression. Melanoma Res 11: 265–273.
33. Woodward JK, Rennie IG, Elshaw SR, Burn JL, Sisley K (2005) Invasive and noninvasive uveal
melanomas have different adhesive properties. Eye (Lond) 19: 342–348.
34. Lawson C, Wolf S (2009) ICAM-1 signaling in endothelial cells. Pharmacol Rep 61: 22–32.
35. Matatall KA, Agapova OA, Onken MD, Worley LA, Bowcock AM, et al. (2013) BAP1 deficiency
causes loss of melanocytic cell identity in uveal melanoma. BMC Cancer 13: 371.

PLOS ONE | DOI:10.1371/journal.pone.0115472 December 15, 2014

15 / 16

Transendothelial Migration by Melanoma Cells

36. Slominski A, Zmijewski MA, Pawelek J (2012) L-tyrosine and L-dihydroxyphenylalanine as hormonelike regulators of melanocyte functions. Pigment Cell Melanoma Res 25: 14–27.
37. Brozyna AA, Jozwicki W, Carlson JA, Slominski AT (2013) Melanogenesis affects overall and
disease-free survival in patients with stage III and IV melanoma. Hum Pathol 44: 2071–2074.
38. Brozyna AA, VanMiddlesworth L, Slominski AT (2008) Inhibition of melanogenesis as a radiation
sensitizer for melanoma therapy. Int J Cancer 123: 1448–1456.
39. Slominski A, Zbytek B, Slominski R (2009) Inhibitors of melanogenesis increase toxicity of
cyclophosphamide and lymphocytes against melanoma cells. Int J Cancer 124: 1470–1477.

PLOS ONE | DOI:10.1371/journal.pone.0115472 December 15, 2014

16 / 16

